[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasopharyngeal-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasopharyngeal-neoplasms":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100618033","ai-system-for-anatomic-recognition--lesion-detection-in-nasopharyngolaryngoscopy-a-prospective-study-100618033",false,"NCT07326358","AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study","Development and Validation of an Artificial Intelligence System for Anatomic Site Recognition and Lesion Detection Based on Electronic Nasopharyngolaryngoscopic Images: A Prospective Multicenter Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Underwent standard electronic nasopharyngolaryngoscopy;\n* Patients who underwent biopsy sampling have a clear pathological diagnosis;\n* Signed a written informed consent form.\n\nExclusion Criteria:\n\n* Image quality is substandard with severe motion artifacts;\n* Lesion images are unclear and incomplete.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","An artificial intelligence-assisted system is trained and validated by collecting nasopharyngolaryngoscopy images from patients.",[24,25],"Nasopharyngeal Neoplasms","Laryngeal Disease","RECRUITING","2025-12-26",{"date":29,"type":30},"2026-01-08","ACTUAL",{"date":32,"type":30},"2025-12-12",{"date":34,"type":20},"2027-03-31",{"name":36,"class":37},"Ruijin Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100578480","phase-2-two-cycle-and-three-cycle-induction-therapy-with-modified-tpf-regimen-combined-and-camrelizumab-for-lanpc-100578480","NCT06811844","Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","Comparison of Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for Locally Advanced Nasopharyngeal Carcinoma: A Prospective, Phase II, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age: 18-65 years old;\n* Pathologically (including histology or cytology) confirmed nasopharyngeal carcinoma patients, with clinical staging T1-4N2-3M0 (according to the UICC\u002FAJCC TNM staging system, 8th edition);\n* No prior systemic treatment (surgery, radiotherapy, chemotherapy, etc.);\n* At least one measurable lesion on imaging (as per RECIST criteria version 1.1);\n* ECOG Performance Status (PS): 0-1;\n* Expected survival ≥3 months;\n* Male subjects and women of childbearing potential must use contraception from the first dose of study medication until 24 weeks after the last dose of study medication;\n* Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests;\n* The investigator believes that the treatment will provide a survival benefit.\n\nExclusion Criteria:\n\n* Active, known, or suspected autoimmune disease;\n* Patients with hypertension that cannot be controlled to normal range despite antihypertensive medication (systolic BP \\>160 mmHg, diastolic BP \\>90 mmHg);\n* History of hereditary bleeding tendency or coagulation dysfunction. Any clinically significant bleeding symptoms within 12 weeks prior to screening, or cumulative bleeding over 50 ml in 24 hours;\n* Unwell-controlled cardiac clinical symptoms or diseases;\n* Interstitial lung disease, drug-induced pneumonia, steroid-treated radiation pneumonitis, active pneumonia with symptoms, or severe pulmonary dysfunction;\n* Active hepatitis B (HBV DNA ≥2000 IU\u002FmL or 10\\^4 copies\u002FmL), hepatitis C (HCV antibody positive and HCV-RNA above the lower limit of detection of the assay);\n* Allergy to any of the study drugs;\n* Pregnant or breastfeeding women;\n* Any other factors that, in the investigator's judgment, may cause premature termination of the study.","65 Years",{"count":48,"type":20},208,"INTERVENTIONAL",[51],"PHASE2","This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.",[24,54,55,56,57],"PD-1 Inhibitor","Induction Therapy","Complete Response","Chemotherapy","2025-06-30",{"date":60,"type":30},"2025-07-01",{"date":62,"type":30},"2025-02-25",{"date":64,"type":20},"2029-12-31",{"name":66,"class":37},"The First Affiliated Hospital of Xiamen University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":49,"phases":78,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100517560","phase-2-nivolumab-in-children-and-adults-with-nasopharyngeal-carcinoma-100517560","NCT06019130","Nivolumab in Children and Adults With Nasopharyngeal Carcinoma","Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma","NPC-Nivo","Inclusion Criteria:\n\n1. Histologically confirmed new diagnosis of nasopharyngeal carcinoma according to the current WHO classification in children and adolescents, aged between 3 years and 17 years, OR histologically confirmed new diagnosis of EBV-positive nasopharyngeal carcinoma, WHO stage II or III, in subjects ≥ 18 years\n2. Stage II or higher in patients ≤ 25 years of age, stage III and IV in patients \\> 25 years of age (AJCC, 8th edition)\n3. Measurable disease by MRI per RECIST 1.1 criteria\n4. Sufficient tumor tissue to be sent for central review, including PD-L1 staining, either as 1 or 2 full blocks (preferred) or a minimum of 25 slides, obtained from core biopsy, punch biopsy, excisional biopsy or surgical specimen\n5. Written informed consent by legal guardians (if patient not ≥ 18 years) and patient prior to study participation\n\nExclusion Criteria:\n\n1. Newly diagnosed nasopharyngeal carcinoma, Stage I in all patients, Stage II in patients \\> 25 years of age\n2. Recurrent nasopharyngeal carcinoma\n3. Nasopharyngeal carcinoma diagnosed as second malignancy and preceding chemotherapy and\u002For radiotherapy\n4. Prior chemotherapy and\u002For radiotherapy\n5. Other active malignancy\n6. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n7. The subject received an investigational drug within 30 days prior to inclusion into this study\n8. Subjects who are enrolled in another clinical trial\n9. Subjects with prior organ allograft or allogenic bone marrow transplantation\n10. Subjects with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.\n11. Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before start of therapy. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n12. Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection\n13. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n14. Inadequate hematologic, renal or hepatic function defined by any of the following screening laboratory values:\n\n    1. WBC \\\u003C 2 000\u002Fµl\n    2. Neutrophils \\\u003C 1 500\u002Fµl\n    3. Platelets \\\u003C 100 x 10e3\u002FµL\n    4. Hemoglobin \\\u003C 9.0 g\u002FdL\n    5. Creatinine \\>1.5 x ULN or creatinine clearance \\\u003C 50 mL\u002Fmin (using the Cockcroft Gault formula or Schwartz formula in patients \\\u003C 18 years)\n    6. AST\u002FALT \\> 3 x ULN (\\> 5 x ULN if liver metastases)\n    7. Total Bilirubin \\> 1.5 x ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level ≥ 3.0 x ULN)\n15. Hearing loss \\> 20 dB loss at 3 kHz due to an inner ear disorder and not caused by tumour burden\n16. History of allergy or hypersensitivity to platinum-containing compounds or other study drug components\n17. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).\n18. Vaccinated with live attenuated vaccines within 4 weeks of the first dose of the study drug.\n19. Adequate performance status (Karnofsky score ≥ 60 for patients (age ≥ 16), Lansky score ≥ 60 (age \\\u003C 16).\n20. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.\n21. The subject has any current or past medical condition and\u002For required medication to treat a condition that could affect the evaluation of the study.\n22. Pregnant females as determined by positive \\[serum or urine\\] hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol. (Please refer to section 4.4)\n23. Lactating females\n24. Subjects, who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities\n25. The subject is unwilling or unable to follow the procedures outlined in the protocol\n26. The subject is mentally or legally incapacitated.","3 Years",{"count":77,"type":20},57,[51],"The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.",[81,82,24,83],"Nasopharyngeal Carcinoma","Nasopharyngeal Cancer","Nasopharynx Cancer",[85,86,87,88,57,89],"Immunotherapy","Nivolumab","Children","Adults","Immune Checkpoint Inhibitor","2024-05-14",{"date":92,"type":30},"2024-05-16",{"date":94,"type":30},"2023-01-10",{"date":96,"type":20},"2028-01-09",{"name":98,"class":37},"German Society for Pediatric Oncology and Hematology GPOH gGmbH",31]